Navigation Links
NovaSperse(SM) Nanoparticle Innovator, PharmaNova, Inc., Awarded Four Government Grants Toward Development of New Therapeutic Products Under Congressional Qualifying Therapeutic Discovery Project Initiative
Date:11/8/2010

VICTOR, N.Y., Nov. 8, 2010 /PRNewswire/ -- PharmaNova, Inc., of Victor, NY, announced today that the Company has been awarded multiple grants worth in excess of $500,000 under the Qualifying Therapeutic Discovery Project (QTDP), which was created by Congress as part of the Patient Protection and Affordable Care Act of 2010. In July, PharmaNova applied for project grants to support development of multiple NovaSperse(SM)-based nanoparticulate products. NovaSperse(SM) is a unique process developed by PharmaNova for the de novo creation of nanoparticles of tightly controlled particle size. The process facilitates particle surface modifications and treatments that further influence solubility, absorption, distribution and e.g. drug-tissue targeting. Grants were awarded to PharmaNova to support further research in the areas of anti-viral treatments; new treatments for ophthalmic disease; targeted delivery of oncology medicines; and the design and development of an implantable drug delivery device. The QTDP is overseen by the Internal Revenue Service and Health & Human Services Department, and is specifically designed to assist small biotech companies engaged in competitive and innovative discoveries in healthcare.

PharmaNova will be exhibiting NovaSperse(SM) nanoparticle technology capabilities (Booth #2256) at the upcoming American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition, 2010 FIP Pharmaceutical Sciences World Congress, New Orleans LA, November 14-18, 2010.

About QTDP

To be eligible, a QTDP must have the potential to develop new treatments that address "unmet medical needs" or chronic and acute diseases; reduce long-term health care costs; represent a significant advance in finding a cure for cancer; advance U.S. competitiveness in the fields of life, biological, and medical sciences; or create or sustain well-paying jobs, either directly or indirectly. Total funds available under the full Government QTDP Program are limited to $1 billion, with a per company limitation of $5 million. QTDP is only available to companies with 250 or less employees.

About PharmaNova

PharmaNova, Inc. is a privately held pharmaceutical company. Our product candidates are derived from the re-positioning and enhancement of known drugs using our proprietary NovaSperse(SM) nanoparticle technology platform. We address low-risk, fast-to-market products in areas of clear medical need and generate revenue from partnering and licensing strategies with commercialization partners and clients worldwide. PharmaNova also conducts contractual formulation development work applying NovaSperse(SM) technology to client-owned products and compounds to support new product development or the extended life cycle management of existing products. PharmaNova has new product candidates in various stages in its development pipeline. Our focus is on the development of novel, improved nanoparticle formulations of ophthalmic, anti-infective and injectable oncology products.

Members of the media, or for further information, please contact Rodney A. Brown, President, PharmaNova, Inc.: rodney.brown@pharmanovaco.com, (1) 585 413-4721.

This press release was issued through eReleases(R).  For more information, visit eReleases Press Release Distribution at http://www.ereleases.com.


'/>"/>
SOURCE PharmaNova Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Targeted Nanoparticles Offer Promise in the Battle Against Cancer
2. Celator(R) Pharmaceuticals Successfully Uses Nanoparticles to Administer Hydrophobic Drug Combinations
3. MicroConstants Now Offers Nanoparticle Formulation Services
4. Small, Smart, Stealth Nanoparticles Seek-and-Destroy Metastatic Cancers, as Epeius Biotechnologies Advances its Intellectual Property Estate With Additional U.S. Patents
5. Researchers Use Nanoparticles as Destructive Beacons to Zap Tumors
6. Hydrox Inc., Cardinal Health Issue Nationwide Recall of Alcohol-Free Mouthwash For Hospitals
7. CMS, Inc., an Elekta Company, Announces First Cancer Patients Treated With Monaco(TM) Radiation Treatment Planning System
8. CardioVascularCS.Org, a division of EndoVascular Forum, Inc., Partners with Complex Interventional Cardiovascular Therapy (CICT) to Extend Electronic Medical Care Advancement
9. Malaria Vaccine Developer, Sanaria Inc., Receives 2009 Vaccine Industry Excellence Award for Best Early-Stage Vaccine Biotech
10. BioStorage Technologies, Inc., Accelerates European Expansion with Opening of New German Facility
11. Nyer Medical Group, Inc., Announces Agreements to Sell Certain Eaton Apothecary Assets to Walgreens and Sell Operating Subsidiarys Stock to Investors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... SAN DIEGO and VANCOUVER, British Columbia, March 27, ... SPHS ) (the "Company" or "Sophiris"), a clinical ... treatment of patients with urological diseases, today reported ... and key corporate highlights. Key ... in Clinical Development for Localized Prostate Cancer. During ...
(Date:3/27/2017)... , March 27, 2017 /PRNewswire/ - INVICTUS MD ... IVITF; FRA: 8IS) Invictus MD is pleased to announce ... shares for trading on the TSX Venture Exchange.  ... TSXV follows a year of significant achievements for Invictus-MD. ... successful test crops at AB Laboratories Inc. ("AB Labs"), ...
(Date:3/27/2017)... , March 27, 2017 The ... reach USD 16.0 billion by 2025, according to a ... prevalence of chronic diseases is anticipated to be responsible ... which thereby widens the scope for growth during the ... bariatric population, which is highly susceptible to chronic diseases, ...
Breaking Medicine Technology:
(Date:3/28/2017)... VA (PRWEB) , ... March 28, 2017 , ... The ... Still, MHA, FRBMA, has begun to serve as its new executive director. Mr. Still ... the Executive Search Committee. , “Bob, as he is known to our members, ...
(Date:3/28/2017)... ... March 28, 2017 , ... Neurotechnology , ... biometric time and attendance tracking products: the new NCheck Cloud Bio Attendance cloud-based ... Attendance uses biometric face recognition to enable users to check in and out ...
(Date:3/28/2017)... St. Petersburg Florida (PRWEB) , ... March 28, 2017 , ... ... U.S. Marine Corp to raise money to for the Toys for Tots Literacy Campaign ... a federal budget in excess of $70 billion, the U.S. ranks at number 14 ...
(Date:3/28/2017)... ... March 28, 2017 , ... Prominant ... Surgical, Inc. is thrilled to offer the recently FDA-approved Obalon Balloon System to ... adds to SkyLex Advanced Surgical’s already comprehensive list of weight-loss services. Dr. ...
(Date:3/28/2017)... ... ... Silicon Valley Hair Institute, the San Francisco Bay Area leader in women's ... loss. Although hair transplant procedures can be seen as more of a man’s issue, ... two reasons a woman may see her hair thinning. , “We are used to ...
Breaking Medicine News(10 mins):